VRCA Insider Trading Activity and SEC Form 4 Filings
VRCA insider trading summary
Over the past 12 months, insiders at Verrica Pharmaceuticals Inc. (VRCA) reported 6 open-market purchases worth $18.0M by 5 insiders and no sales on SEC Form 4. Net insider buying was $18.0M.
Latest VRCA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 25, 2025 | Jayson Rieger | CEO and President | Buy | $400K (94,311 @ $4.24) |
| Nov 25, 2025 | Paul B Manning | Insider | Buy | $5.8M (1,375,380 @ $4.24) |
| Nov 25, 2025 | John J. Kirby | Interim CFO | Buy | $15K (3,536 @ $4.24) |
| Nov 25, 2025 | David Zawitz | Chief Operating Officer | Buy | $42K (10,000 @ $4.24) |
| Nov 25, 2025 | Noah L. Rosenberg | CMO | Buy | $10K (2,357 @ $4.24) |
| Nov 25, 2025 | Paul B Manning | Insider | Buy | $11.7M (2,750,762 @ $4.24) |
| Mar 17, 2025 | Christopher G. Hayes | Chief Legal Officer | Sell | $3K (4,315 @ $0.65) |
| Nov 22, 2024 | Jayson Rieger | CEO and President | Buy | $0 (280,898 @ $0.00) |
| Nov 22, 2024 | Paul B Manning | Insider | Buy | $0 (18,426,966 @ $0.00) |
| Nov 22, 2024 | Paul B Manning | Insider | Buy | $0 (4,494,382 @ $0.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.